Sugi Predict

Sugi Predict / Compounds / SCHEMBL604322

SCHEMBL604322

SCHEMBL604322

O=Cc1cc(F)c(Cl)cc1F

nearest known ligand 0.48

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 4/20 0.43
▸ ERN1 O75460 7/20 0.40
▸ KDM1A O60341 2/20 0.36
▸ KDM1B Q8NB78 1/20 0.36
▸ ALDH1A1 P00352 3/20 0.35
▸ MAPT P10636 1/20 0.32
▸ MEN1 O00255 2/20 0.32
▸ KMT2A Q03164 2/20 0.32
▸ LMNA P02545 1/20 0.32
▸ THRB P10828 1/20 0.32
▸ BLM P54132 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31618920 0.93 TDP1 (0.41) TDP1ERN1KDM1AKDM1BALDH1A1
SCHEMBL1972414 0.93 TDP1 (0.41) TDP1ERN1KDM1AKDM1BALDH1A1
SCHEMBL1965867 0.90 TDP1 (0.43) TDP1ERN1ALDH1A1MEN1KMT2A
SCHEMBL6187165 0.88 TDP1 (0.46) TDP1ERN1KDM1AKDM1BALDH1A1
SCHEMBL30207763 0.85 TDP1 (0.48) TDP1ERN1KDM1AKDM1BALDH1A1
SCHEMBL1808858 0.85 TDP1 (0.48) TDP1ERN1ALDH1A1MEN1KMT2A
SCHEMBL8672712 0.85 TDP1 (0.48) TDP1ERN1KDM1AKDM1BALDH1A1
SCHEMBL248719 0.84 ERN1 (0.50) TDP1ERN1ALDH1A1MEN1KMT2A
SCHEMBL8332206 0.82 PTPN1 (0.44) TDP1ERN1ALDH1A1MAPTMEN1
SCHEMBL1053001 0.82 TDP1 (0.50) TDP1ERN1ALDH1A1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0673912-B1 Process for preparing 2-halogeno-4,5-difluoro-benzofluorides BAYER AG (DE) 1998-12-23 — — EP claimed
CN-115720578-B And tricyclic derivatives, preparation method and medical application thereof 深圳信立泰药业股份有限公司 2025-06-13 — — CN disclosed
US-20240158372-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF AMGEN INC. 2024-05-16 — — US disclosed
US-11813306-B2 Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders NOVARTIS AG (CH) 2023-11-14 — — US disclosed
US-11780826-B2 Bisamide sarcomere activating compounds and uses thereof AMGEN INC. (US) 2023-10-10 — — US disclosed
CN-111601798-B Bisamide sarcomere activating compounds and uses thereof 美国安进公司 2023-08-11 — — CN disclosed
CN-115720578-A Tricyclic derivative, preparation method and medical application thereof 深圳信立泰药业股份有限公司 2023-02-28 — — CN disclosed
US-20220281850-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF AMGEN INC. 2022-09-08 — — US disclosed
US-11299479-B1 Bisamide sarcomere activating compounds and uses thereof CYTOKINETICS, INC. (US) 2022-04-12 — — US disclosed
US-11254658-B2 Bisamide sarcomere activating compounds and uses thereof AMGEN INC. (US) 2022-02-22 — — US disclosed
EP-1791807-A1 THERAPEUTIC DIPHENYL ETHER LIGANDS Pfizer Products Incorporated (US) 2007-06-06 — — EP disclosed
WO-2007056170-A2 PYRROLO[2,1-F] [1,2,4] TRIAZIN-4-YLAMINES IGF-1R KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES BAYER HEALTHCARE AG (DE) 2007-05-18 — — WO disclosed
WO-2007010350-A1 SYNTHESIS OF THERAPEUTIC DIPHENYL ETHERS PFIZER PRODUCTS INC. (US) 2007-01-25 — — WO disclosed
US-20070021634-A1 SYNTHESIS OF THERAPEUTIC DIPHENYL ETHERS PFIZER INC 2007-01-25 — — US disclosed
US-20070021634-A1 SYNTHESIS OF THERAPEUTIC DIPHENYL ETHERS PFIZER INC 2007-01-25 — — US disclosed
WO-2006027684-A1 THERAPEUTIC DIPHENYL ETHER LIGANDS PFIZER PRODUCTS INC. (US) 2006-03-16 — — WO disclosed
US-20060058361-A1 Therapeutic diphenyl ether ligands PFIZER INC 2006-03-16 — — US disclosed
EP-0653412-B1 Process for preparing 4,5-difluorobenzaldehydes BAYER AG (DE) 1998-01-21 — — EP disclosed
US-5489715-A Process for preparing 4,5-difluorobenzaldehydes BAYER AKTIENGESELLSCHAFT (DE) 1996-02-06 — — US disclosed
EP-0653412-A1 Process for preparing 4,5-difluorobenzaldehydes BAYER AG (DE) 1995-05-17 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11254658-B2 Bisamide sarcomere activating compounds and uses thereof TNNI3, TNNT2, TNNC1 TDP1 1362/4885ERN1 1598/4885KDM1A 1404/4885
US-11780826-B2 Bisamide sarcomere activating compounds and uses thereof TNNI3, TNNT2, TNNC1 TDP1 1362/4885ERN1 1598/4885KDM1A 1404/4885
US-20240158372-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF TNNI3, TNNT2, TNNC1 TDP1 1362/4885ERN1 1598/4885KDM1A 1404/4885
US-11813306-B2 Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders PCSK9, PCSK7, PCSK6 TDP1 505/4885ERN1 792/4885KDM1A 2486/4885
US-20070021634-A1 SYNTHESIS OF THERAPEUTIC DIPHENYL ETHERS DHFR, CYP2F1, EPOR TDP1 1719/4885ERN1 1062/4885KDM1A 616/4885
US-20220281850-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF TNNI3, TNNT2, TNNC1 TDP1 1362/4885ERN1 1598/4885KDM1A 1404/4885
US-11299479-B1 Bisamide sarcomere activating compounds and uses thereof TNNI3, TNNT2, TNNC1 TDP1 1362/4885ERN1 1598/4885KDM1A 1404/4885
US-20060058361-A1 Therapeutic diphenyl ether ligands HTR2B, HTR2C, HTR3B TDP1 2051/4885ERN1 4816/4885KDM1A 2000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.